



Manufacturer's Information

Test No. 22-5843/4/5: DNA Database - Saliva

Each sample set consisted of a collection of known buccal cells from three individuals (Items 1-3), provided on either FTA™ Indicating Micro Cards, Bode Buccal® DNA Collectors, or Puritan® Cap-Shure® swabs. Participants were requested to analyze these items using their existing protocols.

SAMPLE PREPARATION: All substrates were prepared from human buccal cheek cells suspended in sterile phosphate-buffered saline solution. The FTA™ Indicating Micro Cards were spotted with 120 µl of the cell suspension, the Bode Buccal® DNA Collectors were spotted with 200 µl of the cell suspension, and the Puritan® Cap-Shure® swabs were spotted with 125 µl of the cell suspension. Item 1 was created using a female donor and Items 2 and 3 were created using two different male donors. The Items were prepared at separate times and were packaged once they were thoroughly dried. Completed sample sets were stored at -20°C until shipment on July 25, 2022.

SAMPLE SET ASSEMBLY: Each item was packed into a pre-labeled item envelope. For each sample set, Items 1, 2, and 3 of the same substrate type were placed into a pre-labeled sample pack envelope and sealed. The sealed sample pack envelopes were then packaged in pre-labeled Heat Seal envelopes and sealed. This process was repeated until all of the sample sets were prepared.

VERIFICATION: Laboratories that conducted predistribution analysis of the samples reported consistent allelic results across all three substrates.

Key to Test Substrates

5843 - FTA™ Indicating Micro Card

5844 - Bode Buccal® Collectors

5845 - Puritan® Cap-Shure® Swabs

Manufacturer's Information, continued
Test No. 22-5843/4/5: DNA Database - Saliva

Amelogenin and STR Results

Results compiled from predistribution laboratories and a consensus of at least 10 participants.

Item	D1S1656	D2S1338	D2S441	D3S1358	D5S818	D6S1043
	D7S820	D8S1179	D10S1248	D12S391	D13S317	D16S539
	D18S51	D19S433	D21S11	D22S1045	Amelogenin	CSF1PO
	FGA	Penta D	Penta E	SE33	TH01	TPOX
	vWA	DYS391	DYS570	DYS576	Y Indel	
1	12,12	20,24	11,11	14,18	11,12	14,21.3
	10,11	11,14	15,17	18,20	11,13	9,12
	16,18	11,13	29,30	15,15	X,X	10,12
	19,24	11,15	10,12	19.2,31.2	6,8	8,10
	16,17	NM	NM	NM	NM	
2	15,17.3	17,17	11,11	14,17	12,13	13,19
	8,11	13,13	13,14	20,22	8,9	8,11
	15,16	10,13	28,29	15,15	X,Y	11,12
	21,21	12,12	7,11	18,18	6,7	9,11
	14,16	11	17	17	2	
3	13,17.3	18,26	11,11	17,18	11,11	11,12
	8,11	11,15	13,16	17,23	11,12	12,13
	12,15	14,14	30,31	11,15	X,Y	10,11
	21,21	13,13	7,12	21.2,30.2	6,7	8,11
	17,17	10	19	17	2	

YSTR Results

Results compiled from predistribution laboratories and a consensus of at least 10 participants.

Item	DYF387S1	DYS19	DYS385	DYS389-I	DYS389-II	DYS390	DYS391	DYS392	DYS393
	DYS437	DYS438	DYS439	DYS448	DYS449	DYS456	DYS458	DYS460	DYS481
	DYS518	DYS533	DYS549	DYS570	DYS576	DYS627	DYS635	DYS643	YGATAH4
2	*	14	11,14	13	29	23	11	13	13
	15	12	11	19	*	17	17	*	22
	*	12	12	17	17	*	23	10	11
3	*	14	14,15	12	28	23	10	11	13
	16	10	12	20	*	14	16	*	26
	*	11	12	19	17	*	22	12	11

* Results were not received from a minimum of 10 participants for the STR and/or YSTR loci indicated.

NM - Non-Male profile, YSTR results not expected.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the results that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.